Results 91 to 100 of about 3,784 (223)

Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report

Medicina, 2021
Pharmacogenomic (PGx) information can guide drug and dose selection, optimize therapy outcomes, and/or decrease the risk of adverse drug events (ADEs). This report demonstrates the impact of a pharmacist-led medication evaluation, with PGx assisted by a ...
Nicole Marie Del Toro-Pagán, Adriana Matos, David Thacker, Jacques Turgeon, Nishita Shah Amin, Veronique Michaud   +5 more
doaj   +1 more source

Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS) [PDF]

, 2017
Huntington disease (HD) is a late onset ultimately fatal neurodegenerative disorder caused by a cytosine-adenine-guanine ( CAG) triplet repeat expansion in the Huntingtin gene which was discovered in 1993. The PHAROS study is a unique observational study
Eberly, Shirley W., Huntington Study Group PHAROS Investigators, Kayson-Rubin, Elise, Oakes, David, Quaid, Kimberly A., Shoulson, Ira   +5 more
core   +1 more source

Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder

Clinical Autonomic Research, 2020
REM sleep behavior disorder (RBD) is a common finding among patients with synucleinopathies. We aimed to determine the degree of autonomic dysfunction in patients presenting with idiopathic RBD (iRBD), and the predictive value of autonomic dysfunction for phenoconversion to a defined neurodegenerative disease.We searched our electronic medical record ...
Stuart J, McCarter, Tonette L, Gehrking, Erik K, St Louis, Mariana D, Suarez, Bradley F, Boeve, Michael H, Silber, Phillip A, Low, Wolfgang, Singer   +7 more
openaire   +3 more sources

Neurologic and psychiatric features of impending neurodegeneration in iRBD

Clinical Parkinsonism & Related Disorders, 2023
Introduction: Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is linked to Parkinson’s disease and other alpha-synucleinopathies, but various subsets of iRBD may not carry equal risk (i.e., those with depression are at higher risk than
Daniel A. Barone, Harini Sarva, Natalie Hellmers, Fei Wang, Zhenxing Xu, Ana C. Krieger, Claire Henchcliffe   +6 more
doaj   +1 more source

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update [PDF]

, 2017
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline,
Bishop, Jeffrey R., Caudle, Kelly E., Dunnenberger, Henry M., Ellingrod, Vicki L., Gaedigk, Andrea, Hicks, J. Kevin, Kharasch, Evan D., Klein, Teri E., Müller, Daniel J., Sangkuhl, Katrin, Shimoda, Kazutaka, Skaar, Todd C., Stingl, Julia C., Swen, Jesse J.   +13 more
core   +1 more source

Lipids under stress - a lipidomic approach for the study of mood disorders [PDF]

, 2015
The emerging field of lipidomics has identified lipids as key players in disease physiology. Their physicochemical diversity allows precise control of cell structure and signaling events through modulation of membrane prop- erties and trafficking of ...
Antonny, Arevalo, Bazinet, Bessa, Björkhem, Bligh, Bozek, Brügger, Buchenauer, Catania, Cermenati, Cerqueira, Cerruti, Chan, Chang, Choi, Chuang, Dawson, De Kroon, Delisi, Di Paolo, Di Paolo, Dias, Dias-Ferreira, Dietschy, Dunkley, Fahy, Fahy, Feder, Giovacchini, Green, Green, Guan, Gulbins, Han, Hannun, Hartmann, Heverin, Holthuis, Holthuis, Huang, Karran, Kassas, Kay, Kielkowska, Kim, Kloda, Klose, Kodigepalli, Kornhuber, Lam, Lamaziere, Lee, Lev, Levant, Little, Liu, Lupien, Lütjohann, Maceyka, Malcher-Lopes, Mapstone, McMahon, McNamara, Mesmin, Miller, Morel, Mouritsen, Movahed, Müller, Nestler, Nestler, Nguyen, Nicolson, Oliveira, Oliveira, Oliveira, Ortolani, Pinto, Piomelli, Popoli, Prasad, Prasad, Puri, Radhakrishnan, Ricart-Jané, Roozendaal, Sanchez, Sanchez-Mejia, Schauder, Schultz, Shevchenko, Simons, Simons, Sousa, Sousa, Sousa, Sousa, Subramanian, Sundaram, Takamori, Thatcher, Tiemeier, Van Meer, Vetrivel, Wakelam, Walter, Wenk, Wenk, Williamson, Wymann, Yang, Zhang, Zhang, Zolov   +114 more
core   +1 more source

Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy. [PDF]

, 2016
BACKGROUND: Huntington's disease (HD) is caused by an unstable polyglutamine (CAG) repeat in the HD gene, whereby a CAG repeat length greater than ∼36 leads to the disease.
Morton, A Jennifer, Sawiak, Stephen J, Wood, Nigel I   +2 more
core   +1 more source

Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder [PDF]

, 2021
Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving \u3b1-synuclein pathology, such as Parkinson's disease, dementia with Lewy ...
Adler, Charles H., Antelmi, Elena, Arnaldi, Dario, Baldelli, Luca, Boeve, Bradley F., Cesari, Matteo, Dall'Antonia, Irene, Diederich, Nico J., Doppler, Kathrin, Dusek, Petr, Ferri, Raffaele, Gagnon, Jean-Francois, Gan-Or, Ziv, Hermann, Wiebke, Hoegl, Birgit, Hu, Michele T., Iranzo, Alex, Janzen, Annette, Kuzkina, Anastasia, Lee, Jee-Young, Leenders, Klaus L., Lewis, Simon J. G., Liguori, Claudio, Liu, Jun, Lo, Christine, Martens, Kaylena A. Ehgoetz, Miglis, Mitchell G., Nepozitek, Jiri, Oertel, Wolfgang H., Plazzi, Giuseppe, Provini, Federica, Puligheddu, Monica, Rolinski, Michal, Rusz, Jan, Stefani, Ambra, Summers, Rebekah L. S., Yoo, Dallah, Zitser, Jennifer   +37 more
core   +1 more source

Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder. [PDF]

EBioMedicine
Joza S, Delva A, Tremblay C, Vo A, Filiatrault M, Tweedale M, Gagnon JF, Postuma RB, Dagher A, Klein J, Hu M, Dusek P, Marecek S, Varga Z, Taylor JP, O'Brien JT, Firbank M, Thomas A, Donaghy PC, Lehéricy S, Isabelle Arnulf, Vidailhet M, Corvol JC, Iceberg Study Group, Camicioli R, Chertkow H, Lewis S, Matar E, Ehgoetz Martens KA, Churchill L, Sommerauer M, Röttgen S, Borghammer P, Knudsen K, Hansen AK, Arnaldi D, Orso B, Mattioli P, Roccatagliata L, Monchi O, Rahayel S.   +40 more
europepmc   +2 more sources

Using a Brief Body Sway Assessment Device to Track Balance Differences across the Huntington's Disease Integrated Staging System Spectrum

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a mutation in the huntingtin gene on chromosome 4, leading to progressive cognitive decline, motor impairment, and functional disability. Although balance impairment is recognized in HD, its onset and evolution with disease stage remain poorly ...
Japleen Kaur, Nadeen Youhanan, Krisha Bagga, Andrew Hall, Paul E. Gilbert, Daniel J. Goble, Jody Corey‐Bloom   +6 more
wiley   +1 more source